GTC Biotherapeutics (fka GTCB)

[brad toland]

I too have wondered about the manner in which you have raised some questions--not the questions themselves--but at least you have stimulated some interesting discussion on this board.

Regarding sepsis, while indeed sepsis is notorious for many product failures, those attempts were using novel chemical entities--I haven't gone back to look but I'm fairly sure about this-- while in this case Leo is hoping to confirm that by restoring the antithrombin level to a more normal level that the DIC can be stopped. I'm sure it remains a very challenging task because the patients are so compromised by the time DIC gets going. Nonetheless, I remain fairly optimistic that antithtrombin will help significantly based on the Kybersept data, the fact that the study consists relacing an existing blood protein which is abnormally low, and the fact that it is being funded by Leo. I expect Leo didn't decide to try this without some serious thought.